■描述巨细胞病毒相关性前葡萄膜炎(CMV-AU)的临床特征以及潜在的合并症,计算并发症发生率,并确定影响南欧地中海人群预后的风险因素和生物标志物。
■这是一个回顾,持续高血压AU患者的多中心病例系列,对局部类固醇治疗没有反应,收集并分析了来自两个葡萄膜炎转诊中心的CMV阳性论文。
■纳入53例聚合酶链反应验证CMV-AU患者的57只眼,平均年龄为48±18岁。确定了四种呈现模式:26.3%为波斯纳-施洛斯曼式,31.6%为慢性AU,19.3%推测为疱疹性葡萄膜炎,12.3%为Fuchs葡萄膜炎综合征样,10.5%,没有具体的初始分类。约15.8%的人接受了口服伐更昔洛韦,22.8%的人接受了伐更昔洛韦外用,61.4%的人都收到了,平均治疗时间为44个月。在23只眼中观察到AU复发,平均每年复发1.5(±1.5)次。唯一与复发显着相关的发现是后粘连(PS)的存在(p=0.034)。更少的角质沉淀物(KP)表明需要更长的处理时间,内皮炎与滤过手术的需要密切相关.
■在这个具有免疫能力的南欧人口中,进一步证实了四种不同的临床表现模式,和可能的生物标志物,如PS,KP,新报告和内皮炎会影响治疗结局.大规模研究可以提供更有效的定制治疗方案。
UNASSIGNED: To describe the spectrum of clinical features of cytomegalovirus-related anterior uveitis (CMV-AU) along with potential comorbidities, to calculate complication rates, and to determine risk factors and biomarkers affecting prognosis in a cohort of a Southern European Mediterranean population.
UNASSIGNED: It is a retrospective, multicenter case series of consecutive patients with persisting hypertensive AU, unresponsive to topical steroids therapy, and CMV-positive essays from two uveitis referral centers were collected and analyzed.
UNASSIGNED: Fifty-seven eyes of 53 patients with polymerase chain reaction-verified CMV-AU over a period of 8 years were included with a mean age of 48 ± 18. Four presentation patterns were identified: 26.3% as Posner-Schlossman-like, 31.6% as chronic AU, 19.3% as presumed herpetic uveitis, 12.3% as Fuchs uveitis syndrome-like, and 10.5% without specific initial classification. About 15.8% received oral valganciclovir, 22.8% received topical valganciclovir, and 61.4% received both, for a mean duration of treatment of 44 months. AU recurrences were observed in 23 eyes with a mean of 1.5 (±1.5) recurrences per year. The only finding significantly associated with recurrence was the presence of posterior synechiae (PS) (p = 0.034). Fewer keratic precipitates (KPs) were indicative for the need of longer treatment, and endotheliitis was strongly associated with the need for filtration surgery.
UNASSIGNED: In this immunocompetent southern European population, four distinct clinical presentation patterns were further confirmed, and possible biomarkers such as PS, KPs, and endotheliitis were newly reported to influence treatment outcomes. Large-scale studies could provide a more effective customized treatment protocol.